PL4332576T3 - Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane - Google Patents
Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszaneInfo
- Publication number
- PL4332576T3 PL4332576T3 PL23202696.3T PL23202696T PL4332576T3 PL 4332576 T3 PL4332576 T3 PL 4332576T3 PL 23202696 T PL23202696 T PL 23202696T PL 4332576 T3 PL4332576 T3 PL 4332576T3
- Authority
- PL
- Poland
- Prior art keywords
- nucleic acid
- acid delivery
- synergistic enhancement
- mixed formulations
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361789375P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4332576T3 true PL4332576T3 (pl) | 2025-09-08 |
Family
ID=50639976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23202696.3T PL4332576T3 (pl) | 2013-03-15 | 2014-03-14 | Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10130649B2 (pl) |
| EP (5) | EP2972360B1 (pl) |
| CY (1) | CY1120507T1 (pl) |
| DK (2) | DK3388834T3 (pl) |
| ES (4) | ES3032013T3 (pl) |
| HR (1) | HRP20180749T1 (pl) |
| HU (2) | HUE071526T2 (pl) |
| LT (1) | LT2972360T (pl) |
| NO (1) | NO3014045T3 (pl) |
| PL (1) | PL4332576T3 (pl) |
| PT (1) | PT2972360T (pl) |
| RS (1) | RS57316B1 (pl) |
| SI (1) | SI2972360T1 (pl) |
| SM (1) | SMT201800264T1 (pl) |
| WO (1) | WO2014144196A1 (pl) |
Families Citing this family (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2782676C (en) | 2009-12-01 | 2021-06-15 | Shire Human Genetic Therapies, Inc. | Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders |
| CA3107288A1 (en) | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| CN103748078B (zh) | 2011-06-08 | 2016-11-09 | 夏尔人类遗传性治疗公司 | 可裂解脂质 |
| EP2859102A4 (en) | 2012-06-08 | 2016-05-11 | Shire Human Genetic Therapies | NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| MX365409B (es) | 2013-03-14 | 2019-05-31 | Shire Human Genetic Therapies | Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados. |
| HUE071526T2 (hu) | 2013-03-15 | 2025-09-28 | Translate Bio Inc | Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
| EP3060303B1 (en) * | 2013-10-22 | 2018-11-14 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
| CA2928040A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Cns delivery of mrna and uses thereof |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| KR20250005450A (ko) | 2014-04-25 | 2025-01-09 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| WO2016118697A1 (en) | 2015-01-21 | 2016-07-28 | Phaserx, Inc. | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| WO2017015463A2 (en) | 2015-07-21 | 2017-01-26 | Modernatx, Inc. | Infectious disease vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017049245A2 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| MA46023A (fr) * | 2015-10-22 | 2019-07-03 | Modernatx Inc | Vaccin contre le virus de la grippe à large spectre |
| TW201729836A (zh) * | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道融合病毒疫苗 |
| CA3002922A1 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| MA46080A (fr) * | 2015-10-22 | 2019-07-10 | Modernatx Inc | Vaccins à base d'acide nucléique contre le virus varicelle-zona (vzv) |
| EP3718565B1 (en) | 2015-10-22 | 2022-04-27 | ModernaTX, Inc. | Respiratory virus vaccines |
| MA46255A (fr) * | 2015-10-22 | 2019-07-31 | Modernatx Inc | Vaccins anticancéreux |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| MA45209A (fr) * | 2015-10-22 | 2019-04-17 | Modernatx Inc | Vaccins contre les maladies sexuellement transmissibles |
| MA46024A (fr) * | 2015-10-22 | 2019-07-03 | Modernatx Inc | Vaccin contre le virus de l'herpès simplex |
| JP7080172B2 (ja) | 2015-12-10 | 2022-06-03 | モデルナティエックス インコーポレイテッド | 治療薬の送達のための組成物及び方法 |
| ES2913626T5 (en) | 2015-12-22 | 2025-05-12 | Modernatx Inc | Compounds and compositions for intracellular delivery of agents |
| US20210206818A1 (en) | 2016-01-22 | 2021-07-08 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| EP3442590A2 (en) | 2016-04-13 | 2019-02-20 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
| EP3458105B1 (en) * | 2016-05-18 | 2024-01-17 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
| US20190298657A1 (en) * | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
| WO2017201349A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
| CA3024507A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease |
| JP7246930B2 (ja) | 2016-05-18 | 2023-03-28 | モデルナティエックス インコーポレイテッド | インターロイキン－１２（ｉｌ１２）をコードするポリヌクレオチドおよびその使用 |
| EP3315125A1 (en) * | 2016-10-31 | 2018-05-02 | Silence Therapeutics (London) Ltd | Lipid nanoparticle formulation |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| JP7560946B2 (ja) * | 2016-11-10 | 2024-10-03 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの皮下送達 |
| AU2017357748B2 (en) * | 2016-11-10 | 2023-11-09 | Translate Bio, Inc. | Improved ice-based lipid nanoparticle formulation for delivery of mRNA |
| EP3582790A4 (en) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | VERY POWERFUL IMMUNOGENIC COMPOSITIONS |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| EP3592728A1 (en) | 2017-03-07 | 2020-01-15 | Translate Bio, Inc. | Polyanionic delivery of nucleic acids |
| JP7220154B2 (ja) | 2017-03-15 | 2023-02-09 | モデルナティエックス インコーポレイテッド | アミノ脂質の結晶形態 |
| WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| EP3596041B1 (en) | 2017-03-15 | 2022-11-02 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| CA3063531A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| WO2018231990A2 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| MA50803A (fr) | 2017-11-22 | 2020-09-30 | Modernatx Inc | Polynucléotides codant pour l'ornithine transcarbamylase pour le traitement de troubles du cycle de l'urée |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| JP7592493B2 (ja) * | 2018-04-18 | 2024-12-02 | オイシン バイオテクノロジーズ，インク． | 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法 |
| KR20210021943A (ko) * | 2018-04-25 | 2021-03-02 | 에트리스 게엠베하 | 미립자 제형용 동결 방지제 |
| AU2019271132A1 (en) * | 2018-05-15 | 2020-11-12 | Translate Bio, Inc. | Subcutaneous delivery of messenger RNA |
| EP3810148A4 (en) * | 2018-06-19 | 2022-06-08 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mrna and long nucleic acids |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| MY205398A (en) | 2018-07-13 | 2024-10-19 | Genmab As | Variants of cd38 antibody and uses thereof |
| JP7534281B2 (ja) | 2018-07-13 | 2024-08-14 | ジェンマブ エー／エス | Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療 |
| EP3841208A1 (en) | 2018-08-24 | 2021-06-30 | Translate Bio, Inc. | Methods for purification of messenger rna |
| WO2020047472A1 (en) * | 2018-08-30 | 2020-03-05 | Research Institute At Nationwide Children's Hospital | Gene therapy for the treatment of galactosemia |
| AU2019335055B2 (en) | 2018-09-04 | 2025-05-29 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| CN112996519B (zh) | 2018-09-04 | 2025-02-28 | 德克萨斯大学系统董事会 | 用于核酸的器官特异性递送的组合物和方法 |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| JP7526168B2 (ja) | 2018-09-19 | 2024-07-31 | モデルナティエックス インコーポレイテッド | Ｐｅｇ脂質及びそれらの使用 |
| US12383508B2 (en) | 2018-09-19 | 2025-08-12 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| EP3856233A1 (en) * | 2018-09-27 | 2021-08-04 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
| EA202190688A1 (ru) | 2018-10-09 | 2021-06-07 | Дзе Юниверсити Оф Бритиш Коламбиа | Композиции и системы, содержащие трансфекционно-компетентные везикулы, не содержащие органических растворителей и детергентов, и связанные с ними способы |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| CA3140423A1 (en) * | 2019-05-14 | 2020-11-19 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| AU2020405214A1 (en) * | 2019-12-20 | 2022-08-11 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
| EP4096710A1 (en) | 2020-01-28 | 2022-12-07 | ModernaTX, Inc. | Coronavirus rna vaccines |
| JP7438604B2 (ja) | 2020-02-07 | 2024-02-27 | モデルナティエックス インコーポレイテッド | ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン |
| WO2021222304A1 (en) | 2020-04-27 | 2021-11-04 | Modernatx, Inc. | Sars-cov-2 rna vaccines |
| US20230226219A1 (en) * | 2020-05-14 | 2023-07-20 | Translate Bio, Inc. | Peg lipidoid compounds |
| WO2021159130A2 (en) | 2020-05-15 | 2021-08-12 | Modernatx, Inc. | Coronavirus rna vaccines and methods of use |
| US20230355743A1 (en) | 2020-09-25 | 2023-11-09 | Modernatx, Inc. | Multi-proline-substituted coronavirus spike protein vaccines |
| CA3094859A1 (en) * | 2020-10-01 | 2022-04-01 | Entos Pharmaceuticals Inc. | Proteolipid vesicles formulated with fusion associated small transmembrane proteins |
| BR112023006710A2 (pt) | 2020-10-14 | 2023-10-03 | George Mason Res Foundation Inc | Métodos de fabricação de nanopartícula lipídica e composições derivadas da mesma |
| TW202233232A (zh) | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| US20240139309A1 (en) | 2021-01-15 | 2024-05-02 | Modernatx, Inc. | Variant strain-based coronavirus vaccines |
| JP2024503698A (ja) | 2021-01-15 | 2024-01-26 | モデルナティエックス インコーポレイテッド | 変異型株ベースのコロナウイルスワクチン |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| JP2024511346A (ja) | 2021-03-15 | 2024-03-13 | モデルナティエックス インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２ ｍｒｎａドメインワクチンの治療的使用 |
| WO2022216787A2 (en) * | 2021-04-08 | 2022-10-13 | City Of Hope | Lipid nanoparticles and methods of use |
| JP2024514182A (ja) | 2021-04-13 | 2024-03-28 | モデルナティエックス インコーポレイテッド | 呼吸器ウイルス組み合わせワクチン |
| EP4322994A1 (en) | 2021-04-14 | 2024-02-21 | ModernaTX, Inc. | Influenza-coronavirus combination vaccines |
| US20250352632A2 (en) * | 2021-05-19 | 2025-11-20 | Daiichi Sankyo Company, Limited | Hpv infectious disease vaccine |
| WO2022245888A1 (en) | 2021-05-19 | 2022-11-24 | Modernatx, Inc. | Seasonal flu rna vaccines and methods of use |
| JP2024528418A (ja) | 2021-06-18 | 2024-07-30 | サノフイ | 多価インフルエンザワクチン |
| WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
| WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| JP2024533234A (ja) | 2021-09-06 | 2024-09-12 | ジェンマブ エー／エス | Ｃｄ２７に結合する能力を有する抗体、そのバリアントおよびその使用 |
| AU2022343710A1 (en) * | 2021-09-07 | 2024-04-18 | The Trustees Of The University Of Pennsylvania | Universal influenza vaccine and methods of use |
| MX2024003615A (es) | 2021-10-08 | 2024-04-09 | Genmab As | Anticuerpos que se unen al cumulo de diferenciacion 30 (cd30) y al cumulo de diferenciacion 3 (cd3). |
| EP4419081A1 (en) | 2021-10-22 | 2024-08-28 | Sail Biomedicines, Inc. | Mrna vaccine composition |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| WO2023079507A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Respiratory syncytial virus rna vaccine |
| WO2023092069A1 (en) | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| CN118488834A (zh) | 2021-11-23 | 2024-08-13 | 赛欧生物医药股份有限公司 | 细菌源性脂质组合物和其用途 |
| IL312997A (en) | 2021-11-30 | 2024-07-01 | Sanofi Pasteur Inc | Human metapneumovirus vaccines |
| US20250360194A1 (en) | 2021-12-08 | 2025-11-27 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
| EP4448103A1 (en) | 2021-12-17 | 2024-10-23 | Sanofi | Lyme disease rna vaccine |
| AU2022421841A1 (en) | 2021-12-20 | 2024-06-27 | Sail Biomedicines, Inc. | Mrna therapeutic compositions |
| WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| WO2023196914A1 (en) | 2022-04-08 | 2023-10-12 | Modernatx, Inc. | Influenza nucleic acid compositions and uses thereof |
| KR20250008765A (ko) | 2022-05-06 | 2025-01-15 | 사노피 | 핵산 백신에 대한 신호 서열 |
| WO2023230481A1 (en) | 2022-05-24 | 2023-11-30 | Modernatx, Inc. | Orthopoxvirus vaccines |
| CN119212720A (zh) | 2022-05-25 | 2024-12-27 | 库瑞瓦格欧洲股份公司 | 编码大肠杆菌FimH抗原性多肽的基于核酸的疫苗 |
| EP4554617A1 (en) | 2022-07-13 | 2025-05-21 | ModernaTX, Inc. | Norovirus mrna vaccines |
| CN120813372A (zh) | 2022-08-22 | 2025-10-17 | 促进军事医学的亨利·M·杰克逊基金会公司 | 针对冠状病毒的疫苗 |
| WO2024050483A1 (en) | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Variant strain-based coronavirus vaccines and uses thereof |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
| CN120112645A (zh) | 2022-11-04 | 2025-06-06 | 赛诺菲巴斯德有限公司 | 用于信使rna加尾的方法 |
| JP2025537539A (ja) | 2022-11-04 | 2025-11-18 | サノフィ パスツール インコーポレイテッド | 呼吸器合胞体ウイルスｒｎａワクチン接種 |
| CN120359023A (zh) | 2022-11-10 | 2025-07-22 | 赛欧生物医药股份有限公司 | 包含脂质纳米颗粒或脂质重构的天然信使包的rna组合物 |
| WO2024119055A1 (en) * | 2022-12-01 | 2024-06-06 | The Regents Of The University Of California | Targeted epigenetic editing as novel therapy for malignant glioma |
| EP4634207A1 (en) | 2022-12-15 | 2025-10-22 | Sanofi Pasteur Inc. | Mrna recombinant capping enzymes |
| EP4633673A1 (en) | 2022-12-15 | 2025-10-22 | Sanofi Pasteur Inc. | Mrna encoding influenza virus-like particle |
| WO2024133884A2 (en) | 2022-12-23 | 2024-06-27 | Sanofi | Optimized tailing of messenger rna |
| AU2024212425A1 (en) | 2023-01-27 | 2025-08-07 | Sail Biomedicines, Inc. | A modified lipid composition and uses thereof |
| EP4658306A1 (en) | 2023-01-30 | 2025-12-10 | ModernaTX, Inc. | Epstein-barr virus mrna vaccines |
| WO2024182301A2 (en) * | 2023-02-27 | 2024-09-06 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding galactose-1-phosphate uridylyltransferase (galt) for the treatment of galactosemia |
| TW202502375A (zh) | 2023-03-02 | 2025-01-16 | 法商賽諾菲公司 | 用於治療披衣菌之組合物 |
| WO2024184489A1 (en) | 2023-03-07 | 2024-09-12 | Sanofi | Manufacture of messenger rna with kp34 polymerase |
| AU2024233180A1 (en) | 2023-03-08 | 2025-09-25 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| AU2024234874A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| AU2024236558A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| WO2024215721A1 (en) | 2023-04-10 | 2024-10-17 | Modernatx, Inc. | Lyme disease vaccines |
| WO2024220712A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Vaccine compositions |
| TW202500750A (zh) | 2023-05-05 | 2025-01-01 | 法商賽諾菲公司 | 用於治療痤瘡的組成物 |
| AR132662A1 (es) | 2023-05-10 | 2025-07-16 | Sanofi Sa | Combinación de vacunas respiratorias de arnm |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| US12410258B2 (en) | 2023-05-12 | 2025-09-09 | Ganmab A/S | Antibodies capable of binding to OX40, variants thereof and uses thereof |
| WO2024254552A1 (en) | 2023-06-08 | 2024-12-12 | Modernatx, Inc. | Stabilized flavivirus vaccines |
| WO2024263826A1 (en) | 2023-06-22 | 2024-12-26 | Modernatx, Inc. | Sars-cov-2 t cell vaccines |
| WO2025003760A1 (en) | 2023-06-28 | 2025-01-02 | Sanofi | Sterol analogs in lipid nanoparticle formulations |
| AR133071A1 (es) | 2023-06-30 | 2025-08-20 | Genmab As | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4 |
| WO2025019352A2 (en) | 2023-07-14 | 2025-01-23 | Modernatx, Inc. | Mers-cov mrna vaccines |
| WO2025017151A1 (en) | 2023-07-18 | 2025-01-23 | Sanofi | Stable poly(a)-encoding messenger rna templates |
| AR133317A1 (es) | 2023-07-19 | 2025-09-17 | Sanofi Sa | Constructos antigénicos de porphyromonas gingivalis |
| WO2025029700A1 (en) | 2023-07-28 | 2025-02-06 | Modernatx, Inc. | Vlp enteroviral vaccines |
| WO2025034612A1 (en) | 2023-08-04 | 2025-02-13 | Modernatx, Inc. | Varicella-zoster virus mrna vaccine |
| WO2025049959A2 (en) | 2023-09-01 | 2025-03-06 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| TW202527960A (zh) | 2023-09-06 | 2025-07-16 | 美商賽諾菲巴斯德公司 | 經修飾ｂ型流感血球凝集素多肽及核酸及其用途 |
| WO2025081042A1 (en) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025134071A1 (en) | 2023-12-22 | 2025-06-26 | Sanofi | Malic and glutaric acid based ionizable lipids |
| WO2025141521A1 (en) | 2023-12-29 | 2025-07-03 | Sanofi | Lipids having dendritic moieties |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025210592A1 (en) | 2024-04-05 | 2025-10-09 | Sanofi Pasteur Inc. | Muscle cell lnp-mrna quality control assays |
| WO2025226656A1 (en) | 2024-04-23 | 2025-10-30 | Modernatx, Inc. | Hepatitis b virus mrna vaccines |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US4946683A (en) | 1987-11-18 | 1990-08-07 | Vestar, Inc. | Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US5976567A (en) | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US5677124A (en) | 1996-07-03 | 1997-10-14 | Ambion, Inc. | Ribonuclease resistant viral RNA standards |
| FR2786104B1 (fr) * | 1998-11-25 | 2002-12-27 | Centre Nat Rech Scient | Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| CA2503043A1 (en) * | 2002-10-18 | 2004-07-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| NZ581166A (en) | 2003-09-15 | 2011-06-30 | Protiva Biotherapeutics Inc | Polyethyleneglycol-modified lipid compounds and uses thereof |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| WO2005121348A1 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| AU2005300638A1 (en) * | 2004-11-05 | 2006-05-11 | Novosom Ag | Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| FR2904144A1 (fr) | 2006-07-19 | 2008-01-25 | St Microelectronics Rousset | Procede de fabrication d'un wafer de semi-conducteur comprenant un filtre optique integre |
| JP2010519203A (ja) | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| CA2930393C (en) | 2007-12-04 | 2022-11-29 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| JP5697988B2 (ja) | 2007-12-27 | 2015-04-08 | プロチバ バイオセラピューティクス インコーポレイティッド | 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法 |
| CA2711236A1 (en) | 2008-01-02 | 2009-07-16 | Alnylam Pharmaceuticals, Inc. | Screening method for selected amino lipid-containing compositions |
| EP3604533A1 (en) | 2008-04-11 | 2020-02-05 | Arbutus Biopharma Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| PL2279254T3 (pl) | 2008-04-15 | 2017-11-30 | Protiva Biotherapeutics Inc. | Nowe preparaty lipidowe do dostarczania kwasów nukleinowych |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| WO2010042877A1 (en) | 2008-10-09 | 2010-04-15 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| JP6087504B2 (ja) | 2008-11-07 | 2017-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | アミノアルコールリピドイドおよびその使用 |
| EP3757090B1 (en) | 2008-11-10 | 2024-06-12 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
| EP2405921A4 (en) | 2009-01-26 | 2013-05-22 | Protiva Biotherapeutics Inc | COMPOSITIONS AND METHODS FOR INACTIVATION OF APOLIPOPROTEIN C-III EXPRESSION |
| KR102229618B1 (ko) | 2009-05-05 | 2021-03-18 | 알닐람 파마슈티칼스 인코포레이티드 | 지질 조성물 |
| SG10201912450XA (en) | 2009-06-10 | 2020-03-30 | Arbutus Biopharma Corp | Improved lipid formulation |
| US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
| WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
| WO2011000108A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein b |
| US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
| CA2782676C (en) | 2009-12-01 | 2021-06-15 | Shire Human Genetic Therapies, Inc. | Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders |
| AU2010328336B2 (en) | 2009-12-07 | 2017-03-02 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| CA2784568A1 (en) | 2009-12-18 | 2011-06-23 | Martin A. Maier | Lipid particles for delivery of nucleic acids |
| WO2011141705A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| US20130323269A1 (en) | 2010-07-30 | 2013-12-05 | Muthiah Manoharan | Methods and compositions for delivery of active agents |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS63430B1 (sr) | 2010-10-01 | 2022-08-31 | Modernatx Inc | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| CN103687957A (zh) | 2011-05-17 | 2014-03-26 | 现代治疗公司 | 工程化核酸及其用于非人类脊椎动物的方法 |
| CA3107288A1 (en) * | 2011-06-08 | 2012-12-13 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| CN103748078B (zh) | 2011-06-08 | 2016-11-09 | 夏尔人类遗传性治疗公司 | 可裂解脂质 |
| EP2755986A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MANIPULATED NUCLEIC ACIDS AND METHOD OF APPLICATION THEREFOR |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2013039861A2 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
| DK3682905T3 (da) | 2011-10-03 | 2022-02-28 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf |
| WO2013066903A1 (en) * | 2011-10-31 | 2013-05-10 | Mallinckrodt Llc | Combinational liposome compositions for cancer therapy |
| WO2013130161A1 (en) | 2011-12-14 | 2013-09-06 | modeRNA Therapeutics | Methods of responding to a biothreat |
| EP2791159A4 (en) | 2011-12-14 | 2015-10-14 | Moderna Therapeutics Inc | MODIFIED NUCLEIC ACIDS AND ACUTE TREATMENT USES THEREOF |
| DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
| WO2013096709A2 (en) | 2011-12-21 | 2013-06-27 | modeRNA Therapeutics | Methods of increasing the viability or longevity of an organ or organ explant |
| WO2013101690A1 (en) | 2011-12-29 | 2013-07-04 | modeRNA Therapeutics | Modified mrnas encoding cell-penetrating polypeptides |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| EP3473611B1 (en) | 2012-02-24 | 2021-10-20 | Arbutus Biopharma Corporation | Trialkyl cationic lipids and methods of use thereof |
| SG10201710631RA (en) | 2012-03-27 | 2018-02-27 | Curevac Ag | Artificial nucleic acid molecules for improved protein or peptide expression |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| CN104411338A (zh) | 2012-04-02 | 2015-03-11 | 现代治疗公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US20150050354A1 (en) | 2012-04-02 | 2015-02-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for the treatment of otic diseases and conditions |
| US20140275229A1 (en) | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| JP6561378B2 (ja) * | 2012-06-08 | 2019-08-21 | トランスレイト バイオ， インコーポレイテッド | 非肺標的細胞へのｍＲＮＡの経肺送達 |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| US9636301B2 (en) | 2012-12-04 | 2017-05-02 | Arbutus Biopharma Corporation | In vitro release assay for liposome encapsulated vincristine |
| ES2968649T3 (es) | 2012-12-07 | 2024-05-13 | Translate Bio Inc | Nanopartículas lipídicas para la administración de ARNm en los pulmones |
| EP2931319B1 (en) | 2012-12-13 | 2019-08-21 | ModernaTX, Inc. | Modified nucleic acid molecules and uses thereof |
| WO2014093574A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
| WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| WO2014158795A1 (en) | 2013-03-12 | 2014-10-02 | Moderna Therapeutics, Inc. | Diagnosis and treatment of fibrosis |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10077439B2 (en) | 2013-03-15 | 2018-09-18 | Modernatx, Inc. | Removal of DNA fragments in mRNA production process |
| WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
| US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
| US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| HUE071526T2 (hu) | 2013-03-15 | 2025-09-28 | Translate Bio Inc | Nukleinsavak bejuttatásának szinergista fokozása kevert kiszerelésekkel |
| RS62529B1 (sr) | 2013-07-11 | 2021-11-30 | Modernatx Inc | Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe |
| US20160151284A1 (en) | 2013-07-23 | 2016-06-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| WO2015024668A2 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Respiratory syncytial virus (rsv) vaccine |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052479A4 (en) | 2013-10-02 | 2017-10-25 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| WO2015058069A1 (en) | 2013-10-18 | 2015-04-23 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
| CN105873902B (zh) | 2013-11-18 | 2019-03-08 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
| WO2015085318A2 (en) | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
| EP2918275B1 (en) | 2013-12-13 | 2016-05-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| CN105874072A (zh) | 2013-12-30 | 2016-08-17 | 库瑞瓦格股份公司 | 人工核酸分子 |
| US20170002060A1 (en) | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| US10307472B2 (en) | 2014-03-12 | 2019-06-04 | Curevac Ag | Combination of vaccination and OX40 agonists |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| KR102459599B1 (ko) | 2014-06-10 | 2022-10-26 | 큐어백 리얼 이스테이트 게엠베하 | Rna생산을 증진하는 방법 및 수단 |
| WO2015196118A1 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| US10286086B2 (en) | 2014-06-19 | 2019-05-14 | Modernatx, Inc. | Alternative nucleic acid molecules and uses thereof |
| WO2015196130A2 (en) | 2014-06-19 | 2015-12-23 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
| PT3766916T (pt) | 2014-06-25 | 2022-11-28 | Acuitas Therapeutics Inc | Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| CA2963271A1 (en) | 2014-10-02 | 2016-04-07 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
| WO2016071857A1 (en) | 2014-11-07 | 2016-05-12 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus expression |
| EP3461904A1 (en) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
| US20170362627A1 (en) | 2014-11-10 | 2017-12-21 | Modernatx, Inc. | Multiparametric nucleic acid optimization |
| EP3247363A4 (en) | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| US20180085474A1 (en) | 2015-01-23 | 2018-03-29 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| US20180245077A1 (en) | 2015-03-20 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
| WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
| WO2016183366A2 (en) | 2015-05-12 | 2016-11-17 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing expression of hepatitis d virus rna |
| US20180245074A1 (en) | 2015-06-04 | 2018-08-30 | Protiva Biotherapeutics, Inc. | Treating hepatitis b virus infection using crispr |
| US10626393B2 (en) | 2015-06-04 | 2020-04-21 | Arbutus Biopharma Corporation | Delivering CRISPR therapeutics with lipid nanoparticles |
| EP3307305A4 (en) | 2015-06-10 | 2019-05-22 | Modernatx, Inc. | TARGETED ADAPTIVE VACCINES |
| HK1248278A1 (zh) | 2015-07-29 | 2018-10-12 | Arbutus Biopharma Corporation | 用於使乙型肝炎病毒基因表达沉默的组合物及方法 |
| US11434486B2 (en) | 2015-09-17 | 2022-09-06 | Modernatx, Inc. | Polynucleotides containing a morpholino linker |
| CA2998370A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a stabilizing tail region |
| WO2017049074A1 (en) | 2015-09-18 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotide formulations for use in the treatment of renal diseases |
| WO2017102010A1 (en) | 2015-12-17 | 2017-06-22 | Biontech Rna Pharmaceuticals Gmbh | Novel cytokine fusion proteins |
| EP3394237A1 (en) | 2015-12-21 | 2018-10-31 | CureVac AG | Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay |
| WO2017109134A1 (en) | 2015-12-22 | 2017-06-29 | Curevac Ag | Method for producing rna molecule compositions |
| EP3394280A1 (en) | 2015-12-23 | 2018-10-31 | CureVac AG | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
| USD787703S1 (en) | 2016-04-26 | 2017-05-23 | Curevac Ag | Inlay for a culture plate |
| KR20210021943A (ko) | 2018-04-25 | 2021-03-02 | 에트리스 게엠베하 | 미립자 제형용 동결 방지제 |
-
2014
- 2014-03-14 HU HUE23202696A patent/HUE071526T2/hu unknown
- 2014-03-14 EP EP14721647.7A patent/EP2972360B1/en active Active
- 2014-03-14 ES ES23202696T patent/ES3032013T3/es active Active
- 2014-03-14 HU HUE14721647A patent/HUE039189T2/hu unknown
- 2014-03-14 SI SI201430708T patent/SI2972360T1/en unknown
- 2014-03-14 HR HRP20180749TT patent/HRP20180749T1/hr unknown
- 2014-03-14 EP EP23202696.3A patent/EP4332576B1/en active Active
- 2014-03-14 LT LTEP14721647.7T patent/LT2972360T/lt unknown
- 2014-03-14 SM SM20180264T patent/SMT201800264T1/it unknown
- 2014-03-14 ES ES18160237T patent/ES2795249T3/es active Active
- 2014-03-14 PL PL23202696.3T patent/PL4332576T3/pl unknown
- 2014-03-14 ES ES20169318T patent/ES2967701T3/es active Active
- 2014-03-14 WO PCT/US2014/028498 patent/WO2014144196A1/en not_active Ceased
- 2014-03-14 DK DK18160237.6T patent/DK3388834T3/da active
- 2014-03-14 PT PT147216477T patent/PT2972360T/pt unknown
- 2014-03-14 ES ES14721647.7T patent/ES2670529T3/es active Active
- 2014-03-14 EP EP18160237.6A patent/EP3388834B1/en active Active
- 2014-03-14 EP EP25177068.1A patent/EP4614148A3/en active Pending
- 2014-03-14 US US14/775,818 patent/US10130649B2/en active Active
- 2014-03-14 EP EP20169318.1A patent/EP3757570B1/en active Active
- 2014-03-14 DK DK14721647.7T patent/DK2972360T3/en active
- 2014-03-14 RS RS20180551A patent/RS57316B1/sr unknown
- 2014-06-26 NO NO14816715A patent/NO3014045T3/no unknown
-
2018
- 2018-05-23 CY CY20181100543T patent/CY1120507T1/el unknown
- 2018-10-10 US US16/157,050 patent/US10646504B2/en active Active
-
2020
- 2020-03-31 US US16/836,513 patent/US12453739B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4332576T3 (pl) | Synergistyczne wzmocnienie dostarczania kwasów nukleinowych poprzez formulacje zmieszane | |
| IL282202A (en) | Compositions and methods for personalized neoplasia vaccines | |
| FR21C1059I2 (fr) | Compositions pharmaceutiques | |
| IL244433B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| DK3030262T3 (da) | Kombineret farmaceutisk sammensætning | |
| EP3065716C0 (en) | FORMULATIONS | |
| EP2970189A4 (en) | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | |
| HRP20180838T1 (hr) | Formuliranje deksmedetomidina u obliku predsmjese | |
| ME03465B (me) | Farmaceutska kompozicija s-ketamin hidrohlorida | |
| DK2943549T3 (da) | Synergistisk h2s-scavenger-sammensætning | |
| IL242545B (en) | Compositions and methods for administering hydrophobic active substances | |
| PL3325080T3 (pl) | Sposoby lepszego dostarczania środków czynnych do guzów | |
| EP2970569A4 (en) | PERSISTENT CARBENE AND COMPOSITIONS WITH IT | |
| EP2958994A4 (en) | Vaccine composition | |
| PL3154515T3 (pl) | Udoskonalenia kompozycji donosowych i sposób ich stosowania | |
| IL262252B (en) | Therapeutic compositions and methods involving mrna transfection | |
| PL3042669T3 (pl) | Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy | |
| EP3012307A4 (en) | MIXED REFRIGERANT | |
| DK3316856T3 (da) | Blandede formuleringer | |
| BR112015002646A2 (pt) | composto e composição farmacêutica | |
| IL244537A0 (en) | New administration preparations and methods of their use | |
| FI20135772L (fi) | Vuorovaikutteisia aineosia sisältävät koostumukset | |
| DK3060213T3 (da) | Farmaceutiske sammensætninger omfattende antibakterielle midler | |
| PL2956129T3 (pl) | Kompozycje farmaceutyczne zawierające deksketoprofen i tramadol | |
| PT3041488T (pt) | Composições de mel |